Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study

Diabetes Obes Metab. 2018 Feb;20(2):438-442. doi: 10.1111/dom.13061. Epub 2017 Aug 22.

Abstract

This study aimed to assess the effect of luseogliflozin on liver fat deposition and compare luseogliflozin to metformin in type 2 diabetes (T2D) patients with non-alcoholic fatty liver disease (NAFLD). Thirty-two T2D patients with NAFLD diagnosed by computed tomography or abdominal sonography were recruited. Participants were randomly assigned to receive either luseogliflozin (2.5 mg, newly administered) or metformin (1500 mg, newly or additionally administrated). Data on the liver-to-spleen attenuation ratio (L/S), visceral fat area, body mass index, glycated hemoglobin (HbA1c), alanine aminotransferase (ALT), fasting plasma glucose, C-peptide immunoreactivity (CPR), and CPR index were collected at baseline and after 6 months. The change in L/S was significantly greater in the luseogliflozin group than in the metformin group. Similarly, the changes in the visceral fat area, HbA1c, and body mass index were significantly greater in the luseogliflozin group than in the metformin group. The changes in ALT, fasting glucose, CPR, and CPR index were not significant in both groups. In conclusion, luseogliflozin significantly reduced liver fat deposition as compared to metformin, which may indicate clinical relevant benefits for NAFLD.

Keywords: SGLT2 inhibitor; antidiabetic drug; fatty liver.

Publication types

  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Adiposity / drug effects
  • Diabetes Mellitus, Type 2 / blood
  • Diabetes Mellitus, Type 2 / complications
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / metabolism
  • Drug Therapy, Combination / adverse effects
  • Female
  • Glycated Hemoglobin A / analysis
  • Humans
  • Hypoglycemic Agents / adverse effects
  • Hypoglycemic Agents / therapeutic use
  • Lipid Metabolism / drug effects*
  • Lipotropic Agents / therapeutic use*
  • Liver / diagnostic imaging
  • Liver / drug effects
  • Liver / metabolism
  • Liver / pathology
  • Male
  • Membrane Transport Modulators / adverse effects
  • Membrane Transport Modulators / therapeutic use*
  • Metformin / adverse effects
  • Metformin / therapeutic use
  • Middle Aged
  • Non-alcoholic Fatty Liver Disease / complications
  • Non-alcoholic Fatty Liver Disease / diagnostic imaging
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Organ Size / drug effects
  • Pilot Projects
  • Sodium-Glucose Transporter 2 / metabolism
  • Sorbitol / adverse effects
  • Sorbitol / analogs & derivatives*
  • Sorbitol / therapeutic use
  • Tomography, X-Ray Computed
  • Ultrasonography
  • Weight Loss / drug effects

Substances

  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Lipotropic Agents
  • Membrane Transport Modulators
  • SLC5A2 protein, human
  • Sodium-Glucose Transporter 2
  • hemoglobin A1c protein, human
  • Sorbitol
  • Metformin
  • 1,5-anhydro-1-(5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl)-1-thioglucitol